mRNA vaccines in oncology

mRNA vaccines, initially developed for infectious diseases like COVID-19, are now being explored for cancer treatment. Researchers are investigating their potential to train the immune system to attack cancer cells specifically.

Melanoma trial results

A recent trial called INTerpath-001 showed that a personalized mRNA vaccine called intismeran reduced the risk of melanoma recurrence or death by 42 percent in patients who had already undergone surgery and received pembrolizumab as adjuvant therapy.

How the vaccine works

The vaccine is created using DNA from the patient's own tumor and normal tissue. This personalized approach aims to trigger a stronger and more targeted immune response against cancer cells.

Current challenges in melanoma treatment

Despite the use of anti-PD-1 drugs like pembrolizumab as adjuvant therapy, many melanoma patients still experience recurrence. Double immunotherapies with checkpoint inhibitors have not shown survival benefits, prompting the search for alternative treatments.

Esmo congress highlights

The findings from the INTerpath-001 trial were presented at the European Society for Medical Oncology (Esmo) congress in Madrid, where experts emphasized the growing interest in mRNA vaccines as a promising avenue in oncology.